Predicting and evaluating response to omalizumab in patients with severe allergic asthma.

@article{Bousquet2007PredictingAE,
  title={Predicting and evaluating response to omalizumab in patients with severe allergic asthma.},
  author={Jean Bousquet and Klaus Friedrich Rabe and Marc Humbert and Kian Fan Chung and William Berger and H. G. Fox and Gareth Ayre and Hungta Chen and Karen Kruse Thomas and Martin Blogg and Stephen Holgate},
  journal={Respiratory medicine},
  year={2007},
  volume={101 7},
  pages={1483-92}
}
BACKGROUND Omalizumab is a monoclonal antibody indicated for treatment of severe persistent allergic asthma inadequately controlled despite optimal controller therapy. We investigated whether patient selection could be targeted further. METHODS Data from seven randomized controlled omalizumab trials were analyzed to investigate whether pre-treatment patient baseline clinical characteristics could be identified that were predictive of a superior response to omalizumab. We also studied whether… CONTINUE READING